Literature DB >> 12447694

Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential.

Yasushi Yatabe1, Hirotaka Osada, Yoshio Tatematsu, Tetsuya Mitsudomi, Takashi Takahashi.   

Abstract

We recently reported that 14-3-3sigma is frequently inactivated in small cell lung cancer (SCLC) and a part of large cell carcinomas. Subsequent studies revealed that the large cell carcinomas could be morphologically categorized as large cell neuroendocrine carcinomas (LCNEC). The present study therefore examines 14-3-3sigma expression in a spectrum of neuroendocrine lung tumors, which had varied p53 status, proliferative activity and clinical aggressiveness. The expression of 14-3-3sigma was decreased in all four categories of the spectrum, (5 out of 5 typical carcinoids, 2 out of 2 atypical carcinoids, 5 out of 7 LCNECs and 15 out of 18 SCLCs). In sharp contrast, the level of 14-3-3sigma expression in 75 non-small cell lung cancers (NSCLCs) was the same as that in normal lung tissue, with only one exception. The expression status of neuroendocrine tumors and NSCLCs was not affected by p53 status, but dense promoter hypermethylation of the 14-3-3sigma gene was specifically observed in neuroendocrine tumors, suggesting that methylation plays a regulatory role in 14-3-3sigma expression in vivo as well as in vitro. Furthermore, the expression was not only down-regulated in pulmonary neuroendocrine tumors, but also in neuroendocrine tumors arising from various other organs, through examination of 123 non-pulmonary tumors. Since various carcinogenic machineries are involved in the neuroendocrine tumors, a reduced expression of 14-3-3sigma might be required for the development of neuroendocrine tumors. Constitutive 14-3-3sigma expression was distributed exclusively in putative stem cells of the normal lung, namely the basal cells of the bronchus, and type II pneumocytes. Notably, 14-3-3sigma expression was up-regulated during the regeneration of type II pneumocytes, suggesting that 14-3-3sigma plays a biological role when a regenerative and/or differentiating drive is activated, facilitating exit from stem cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447694     DOI: 10.1038/sj.onc.1206014

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.

Authors:  S M Pulukuri; J S Rao
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

2.  14-3-3sigma, the double-edged sword of human cancers.

Authors:  Zhaomin Li; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Am J Transl Res       Date:  2009-06-08       Impact factor: 4.060

3.  Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.

Authors:  Zhaomin Li; Zizheng Dong; David Myer; Michele Yip-Schneider; Jianguo Liu; Ping Cui; C Max Schmidt; Jian-Ting Zhang
Journal:  BMC Cancer       Date:  2010-11-01       Impact factor: 4.430

4.  Interaction of 14-3-3σ with KCMF1 suppresses the proliferation and colony formation of human colon cancer stem cells.

Authors:  Jian Zou; Lin Mi; Xiao-Feng Yu; Jie Dong
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

5.  14-3-3σ induces heat shock protein 70 expression in hepatocellular carcinoma.

Authors:  Chia-Chia Liu; Yee-Jee Jan; Bor-Sheng Ko; Yao-Ming Wu; Shu-Man Liang; Shyh-Chang Chen; Yen-Ming Lee; Tzu-An Liu; Tzu-Ching Chang; John Wang; Song-Kun Shyue; Li-Ying Sung; Jun-Yang Liou
Journal:  BMC Cancer       Date:  2014-06-12       Impact factor: 4.430

Review 6.  The mechanobiome: a goldmine for cancer therapeutics.

Authors:  Eleana Parajón; Alexandra Surcel; Douglas N Robinson
Journal:  Am J Physiol Cell Physiol       Date:  2020-11-11       Impact factor: 4.249

7.  The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas.

Authors:  Zhihui Wang; Claes G Tropè; Zhenhe Suo; Gunhild Trøen; Guanrui Yang; Jahn M Nesland; Ruth Holm
Journal:  BMC Cancer       Date:  2008-10-24       Impact factor: 4.430

8.  Differential tissue-specific protein markers of vaginal carcinoma.

Authors:  K Hellman; A A Alaiya; S Becker; M Lomnytska; K Schedvins; W Steinberg; A-C Hellström; S Andersson; U Hellman; G Auer
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.